Component

Human serum L-carnitine concentration

Human serum L-carnitine concentration. Species, exposure and limitations are retained in each linked claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Serum L-carnitine increased compared with placebo.

    Mangiferin → Human serum L-carnitine concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/mangiferin-research/25989216.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "2f57445ffe1eb20de3c2bf1170d152c358be1d7763cef2a091c0b3052040e539", "start_char": 0, "end_char": 1522, "text_sha256": "2f57445ffe1eb20de3c2bf1170d152c358be1d7763cef2a091c0b3052040e539"}
    experimental_model
    Double-blind randomized placebo-controlled trial
    exposure
    Mangiferin 150 mg/day for 12 weeks
    limitations
    One trial in a selected population; biomarkers do not demonstrate clinical outcomes or directly measure fatty-acid flux.
    nutrient_topic
    Mangiferin research collection; topical membership is not evidence of a direct dietary effect. · Mangiferin
    organism
    Overweight adults with hyperlipidemia; 97 completers
    plain_language
    A metabolite used in fatty-acid handling was higher in blood.
    primary_references
    [mangiferin-p25989216] Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial. (2015). https://pubmed.ncbi.nlm.nih.gov/25989216/ DOI: 10.1038/srep10344
    tissue_or_cell_type
    Serum metabolic measurements

    Mangiferin: metabolism, signaling and nutrient connections (2026-09-17) · lines 1199–1210

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind randomized placebo-controlled trial · source_derived_draft · unverified_draft

    ### mangiferin-trial-carnitine Serum L-carnitine increased compared with placebo. Condition category: normal nutrient_topic: Mangiferin research collection; topical membership is not evidence of a direct dietary effect. plain_language: A metabolite used in fatty-acid handling was higher in blood. organism: Overweight adults with hyperlipidemia; 97 completers tissue_or_cell_type: Serum metabolic measurements experimental_model: Double-blind randomized placebo-controlled trial limitations: One trial in a selected population; biomarkers do not demonstrate clinical outcomes or directly measure fatty-acid flux. exposure: Mangiferin 150 mg/day for 12 weeks evidence_span: {"source_cache": "artifacts/mangiferin-research/25989216.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "2f57445ffe1eb20de3c2bf1170d152c358be1d7763cef2a091c0b3052040e539", "start_char": 0, "end_char": 1522, "text_sha256": "2f57445ffe1eb20de3c2bf1170d152c358be1d7763cef2a091c0b3052040e539"} [mangiferin-p25989216] Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial. (2015). https://pubmed.ncbi.nlm.nih.gov/25989216/ DOI: 10.1038/srep10344
    Complete structured claim and evidence
  2. Twelve days of pivmecillinam reduced mean serum free carnitine from 42.8 to 11.6 micromolar, while measured muscle carnitine was unchanged.

    Pivmecillinam → Human serum L-carnitine concentration source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    nutrient_deficiency Imported condition classification; unverified.
    evidence_access
    Primary abstract
    experimental_model
    Six healthy men; 1200 mg/day.
    limitations
    A small provocation study, not a universal drug effect size.
    nutrient_topic
    L-Carnitine collection; isomer, preparation, species, exposure and manipulation remain explicit. · L-Carnitine
    plain_language
    A drug-associated shortfall can differ between blood and muscle.
    primary_references
    Impaired ketogenesis in carnitine depletion caused by short-term administration of pivalic acid prodrug. · 1994 · https://pubmed.ncbi.nlm.nih.gov/7917463/ · DOI 10.1006/bmmb.1994.1028
    trigger_kind
    nutrient_deficiency Imported condition classification; unverified.

    L-Carnitine: synthesis, acyl-group transport, fuel selection and nutrient interactions (2026-09-19) · lines 266–272

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Six healthy men; 1200 mg/day. · source_derived_draft · unverified_draft

    ## l-carnitine-pivalate-depletion A drug-associated shortfall can differ between blood and muscle. Twelve days of pivmecillinam reduced mean serum free carnitine from 42.8 to 11.6 micromolar, while measured muscle carnitine was unchanged. Model: Six healthy men; 1200 mg/day. Limitations: A small provocation study, not a universal drug effect size. Evidence access: Primary abstract Impaired ketogenesis in carnitine depletion caused by short-term administration of pivalic acid prodrug. · 1994 · https://pubmed.ncbi.nlm.nih.gov/7917463/ · DOI 10.1006/bmmb.1994.1028
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. After pivmecillinam-associated carnitine depletion, two of six subjects showed impaired ketone production during a 36-hour fast.

    Experimental context and source evidence
    availability_state
    nutrient_deficiency Imported condition classification; unverified.
    evidence_access
    Primary abstract
    experimental_model
    Human before-and-after fasting challenge.
    limitations
    Only a subset was affected; no universal plasma cutoff or dietary diagnosis was established.
    nutrient_topic
    L-Carnitine collection; isomer, preparation, species, exposure and manipulation remain explicit. · L-Carnitine
    plain_language
    Low carnitine can limit the switch to fat-derived fasting fuel.
    primary_references
    Impaired ketogenesis in carnitine depletion caused by short-term administration of pivalic acid prodrug. · 1994 · https://pubmed.ncbi.nlm.nih.gov/7917463/ · DOI 10.1006/bmmb.1994.1028
    trigger_kind
    nutrient_deficiency Imported condition classification; unverified.

    L-Carnitine: synthesis, acyl-group transport, fuel selection and nutrient interactions (2026-09-19) · lines 274–280

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Human before-and-after fasting challenge. · source_derived_draft · unverified_draft

    ## l-carnitine-pivalate-ketones Low carnitine can limit the switch to fat-derived fasting fuel. After pivmecillinam-associated carnitine depletion, two of six subjects showed impaired ketone production during a 36-hour fast. Model: Human before-and-after fasting challenge. Limitations: Only a subset was affected; no universal plasma cutoff or dietary diagnosis was established. Evidence access: Primary abstract Impaired ketogenesis in carnitine depletion caused by short-term administration of pivalic acid prodrug. · 1994 · https://pubmed.ncbi.nlm.nih.gov/7917463/ · DOI 10.1006/bmmb.1994.1028
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards